View Latest Medical and Pharma Bids and Tenders

Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products With The Active Ingredients Lamivudine, Tenofovir Disoproxil And Doravirine (J05Ar24) As Part Of A So-Called Open-House Model.

Open House Drug Discount Agreements Lamivudine, Tenofovir Disoproxil And Doravirine, Atc J05Ar24

Open House Drug Discount Agreements Lamivudine, Tenofovir Disoproxil And Doravirine, Atc J05Ar24

Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products With The Active Ingredients Lamivudine, Tenofovir Disoproxil And Doravirine (J05Ar24) As Part Of A So-Called Open-House Model.

Completion Of A Non-Exclusive Discount Contract According To Section 130C Paragraph 1 Sgb V For Doravirin, Lamivudine, Tenofovir Disoproxil Fumarate, Atc Code: J05Ar24 For The Period From December 1St, 2023 To November 30Th, 2025

Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate, Atc J05Ar24 For The Period December 1St, 2023 - November 30Th, 2025

Open House Original Discount Agreements 2023-29 - Dolutegravir/Lamivudine (Combination Of Active Ingredients)

Open House Original Discount Contracts 2023-28 - Doravirin, Lamivudine, Tenofovir

Open House Original Discount Agreements 2023-29 - Dolutegravir/Lamivudine (Combination Of Active Ingredients)

Open House Original Discount Agreements 2023-28 - Doravirine, Lamivudine, Tenofovir